Suppr超能文献

治疗睡眠功能障碍和精神障碍。

Treatment of sleep dysfunction and psychiatric disorders.

机构信息

Philip M. Becker, MD Program in Sleep Medicine, Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5477 Glen Lakes Drive #100, Dallas, TX 75231, USA.

出版信息

Curr Treat Options Neurol. 2009 Sep;11(5):349-57. doi: 10.1007/s11940-009-0039-z.

Abstract

Patients with neurologic disorders commonly experience sleep dysfunction and psychiatric disorders. The most common sleep dysfunction is insomnia, which is a primary symptom in 30% to 90% of psychiatric disorders. Insomnia and fatigue are prominent symptoms of anxiety disorders and major depression that may occur in patients who are treated but have residual sleep dysfunction. Anxiety and depressive disorders account for 40% to 50% of all cases of chronic insomnia. It is also recognized that primary insomnia and other primary sleep disorders produce symptoms that are similar to those reported by patients with psychiatric disorders. A clinician must judge whether sleep deprivation causes mood disturbance or whether depressive or anxiety disorder represents the primary reason for sleep dysfunction. When insomnia is comorbid with mild to moderate depression, therapy should begin with bedtime dosing of sedating antidepressants such as mirtazapine, nefazodone, or tricyclic antidepressants, which are preferred because of their sedative effects. Often side effects limit their usefulness. Intervention for chronic insomnia is similar in nonpsychiatric and psychiatric patients. Behavioral therapies, particularly multicomponent cognitive-behavioral therapy, and lifestyle changes show significant long-term efficacy as treatments for chronic insomnia. The most studied pharmacologic agents to treat insomnia are sedative hypnotic agents, particularly those that are active through the benzodiazepine receptor-GABA (gamma-aminobutyric acid) complex, such as benzodiazepines, eszopiclone, zaleplon, and zolpidem. Melatonin and the melatonin-receptor agonist ramelteon have not had adequate study in psychiatric patients to define their use, but small studies suggest benefit. Prescription of adjunctive trazodone (50-150 mg) is a common clinical practice to treat comorbid insomnia during antidepressant therapy, but published data are surprisingly limited, considering its frequent use. Although there has been insufficient research on the use of atypical antipsychotic agents in severe insomnia, psychiatrists use quetiapine, olanzapine, or others to lessen agitation that disrupts sleep. When insomnia or hypersomnia continue even as mood, anxiety, or thought disorders improve with standard therapy, the physician should consider the potential presence of underlying sleep disorders.

摘要

患有神经系统疾病的患者通常会经历睡眠功能障碍和精神障碍。最常见的睡眠功能障碍是失眠,它是 30%至 90%精神障碍的主要症状。失眠和疲劳是焦虑症和重度抑郁症的突出症状,即使经过治疗,仍可能存在睡眠功能障碍的患者中出现。焦虑症和抑郁症占所有慢性失眠症的 40%至 50%。人们还认识到,原发性失眠和其他原发性睡眠障碍产生的症状与精神障碍患者报告的症状相似。临床医生必须判断是睡眠剥夺导致情绪紊乱,还是抑郁或焦虑障碍是睡眠功能障碍的主要原因。当失眠与轻度至中度抑郁共病时,治疗应从睡前服用镇静抗抑郁药开始,如米氮平、奈法唑酮或三环类抗抑郁药,由于它们具有镇静作用,因此优先选用。但通常副作用会限制其使用。非精神科和精神科患者的慢性失眠干预措施相似。行为疗法,特别是多成分认知行为疗法和生活方式改变,作为慢性失眠的治疗方法具有显著的长期疗效。研究最多的治疗失眠的药物是镇静催眠药,特别是那些通过苯二氮䓬受体-γ-氨基丁酸(GABA)复合物发挥作用的药物,如苯二氮䓬类、唑吡坦、扎来普隆和佐匹克隆。褪黑素和褪黑素受体激动剂雷美尔酮在精神科患者中的研究不足,无法确定其用途,但小型研究表明它们有一定的益处。在抗抑郁治疗期间,开辅助曲唑酮(50-150mg)是一种常见的临床实践,以治疗共病性失眠,但考虑到其频繁使用,发表的数据却惊人地有限。尽管在严重失眠症中使用非典型抗精神病药物的研究不足,但精神科医生使用喹硫平、奥氮平或其他药物来减轻扰乱睡眠的激越。即使在标准治疗改善情绪、焦虑或思维障碍后,失眠或嗜睡仍持续存在,医生应考虑潜在的睡眠障碍的可能性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验